Applied Science Products, Inc., (PINKSHEETS: APLD), is pleased to announce the appointment of Dr. David Shulkin, President of Morristown Memorial Hospital, a 642 bed comprehensive Medical Center, and part of Atlantic Health Systems. Dr. Shulkin brings a vast amount of experience and expertise in the healthcare area enriching the company's plans for its plasma-based products in the coming years.

In 2009 Dr. Shulkin was named one of the One Hundred Most Influential People in American Healthcare by Modern Healthcare and for the second year in a row was recognized among the "50 Most Powerful Physician Executives in the Country" (ranked as #14 in 2009 and #12 in 2008) by Modern Healthcare and Modern Physician. Previously, Dr. Shulkin was President and CEO of Beth Israel Medical Center in New York. He has served in numerous physician leadership roles including the Chief Medical Officer of the University of Pennsylvania Health System, the Hospital of the University of Pennsylvania, Temple University Hospital, and the Medical College of Pennsylvania Hospital. Dr. Shulkin also served in academic positions including the Chairman of Medicine and Vice Dean at Drexel University School of Medicine.

Dr. Shulkin was also founder, Chairman and CEO of DoctorQuality, Inc., one of the first consumer oriented sources of information for quality and safety in healthcare. Dr. Shulkin has been on the editorial boards of numerous journals including the Journal of the American Medical Association and Hospital Physician, and is on the editorial boards of the Journal of Safety, the Journal of Clinical Outcomes Management and the Journal of Disease Mangement. Dr. Shulkin is also widely published.

"We're very gratified to have Dr. Shulkin join our board," said Kenneth Wood, CEO of Applied Science Products, Inc. "As a recognized leader in his field, his experience, and entrepreneurial background will be an invaluable asset in the development and strategic marketing of our proprietary plasma-based technology, especially since we have significant opportunity within the healthcare market sector. We look forward to working with him."

Shulkin remarked, "I'm very pleased to join the Board of ASP. I think the company's plasma technology is exciting and diverse in application. Any time you can efficiently implement microbial destruction technology into useful end products, you have opportunity to address a number of problems facing the world today."

Dr. Shulkin is a board certified internist, a fellow of the American College of Physicians, Professor of Medicine at Albert Einstein School of Medicine and a Senior Fellow at the Health Research and Education Trust of the American Hospital Association, a Senior Fellows at the School of Population Health at Thomas Jefferson University, and a Senior Fellow (Adjunct) at the Leonard Davis Institute in Health Economics at the University of Pennsylvania.

Dr. Shulkin received his medical degree from the Medical College of Pennsylvania, his internship at Yale University School of Medicine, and a residency and Fellowship in General Medicine at the University of Pittsburgh Presbyterian Medical Center. He received advanced training in outcomes research and economics as a Robert Wood Johnson Foundation Clinical Scholar at the University of Pennsylvania.

Dr. Shulkin has received numerous awards and was named one of the country's top Health care leaders for the next century by Modern Healthcare, an international Leader in Health Care Award by the Healthcare Forum.

About Advanced Plasma Products, Inc. Advanced Plasma Products, Inc (APP) is a wholly owned subsidiary of Applied Science Products, Inc. APP is a growth stage technology company dedicated to developing and commercializing needed and useful products based upon its patented platform One Atmosphere Uniform Glow Discharge Plasma (OAUGDP) technology. APP's intent is to leverage its unique atmospheric plasma technology into development of a number of products in diverse, high growth markets, such as healthcare, air purification, disinfection, manufacturing, and biotechnology. The company has previously released its TriClean Pro air purification product that includes the company's newest advanced plasma design. The TriClean Pro is a robust air sanitizer that effectively traps and destroys all known classes of microorganisms such as pathogenic bacteria, viruses, allergens and mold. It also removes odor-causing volatile organic compounds (VOC's) providing a comprehensive approach to air purification.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: This release contains forward looking statements identified by the use of words such as should, believes, plans, goals, expects, may, will, objectives, missions, or the negative thereof, other variations thereon or comparable terminology. Such statements are based on currently available information which management has assessed but which is dynamic and subject to rapid change due to risks and uncertainties that affect our business such as the impact of competitive products and pricing, limited visibility into future product demand, slower economic growth generally, difficulties inherent in the development of complex technology, new products sufficiency, availability of capital to fund operations, research and development, fluctuations in operating results, and other risks that may be identified and detailed from time to time. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and should be considered forward looking statements. Forward looking statements involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated.

Contact: Kenneth Wood Chief Executive Officer Applied Science Products, Inc. (908) 507-6239